301331 恩威医药
交易中 01-21 14:33:09
资讯
新帖
简况
恩威医药最新公告：2025年净利润同比预增50.68%至77.35%
证券之星 · 01-20 17:49
恩威医药最新公告：2025年净利润同比预增50.68%至77.35%
恩威医药（301331）披露2025年中期分红派息实施公告，12月31日股价上涨0.23%
证券之星 · 2025-12-31
恩威医药（301331）披露2025年中期分红派息实施公告，12月31日股价上涨0.23%
恩威医药（301331）披露2025年中期分红方案，12月29日股价下跌0.34%
证券之星 · 2025-12-29
恩威医药（301331）披露2025年中期分红方案，12月29日股价下跌0.34%
恩威医药：海南定安恩威实业有限公司与公司已无关联
证券之星 · 2025-12-24
恩威医药：海南定安恩威实业有限公司与公司已无关联
恩威医药（301331）披露关于控股股东部分股份解除质押的公告，12月8日股价上涨0.03%
证券之星 · 2025-12-08
恩威医药（301331）披露关于控股股东部分股份解除质押的公告，12月8日股价上涨0.03%
恩威医药：呼吸系统用药是公司重要的产品线之一
证券日报 · 2025-11-20
恩威医药：呼吸系统用药是公司重要的产品线之一
恩威医药（301331）股东成都恩威投资(集团)有限公司质押500万股，占总股本4.86%
证券之星 · 2025-11-20
恩威医药（301331）股东成都恩威投资(集团)有限公司质押500万股，占总股本4.86%
恩威医药：多款产品可用于流感治疗
证券之星 · 2025-11-20
恩威医药：多款产品可用于流感治疗
恩威医药（301331）披露2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市公告，11月14日股价下跌0.77%
证券之星 · 2025-11-14
恩威医药（301331）披露2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市公告，11月14日股价下跌0.77%
恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金
证券之星 · 2025-11-14
恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金
恩威医药（301331）2025年三季报简析：营收净利润同比双双增长
证券之星 · 2025-10-31
恩威医药（301331）2025年三季报简析：营收净利润同比双双增长
恩威医药（301331）披露2023年限制性股票激励计划第二期归属条件成就，10月30日股价下跌4.28%
中金财经 · 2025-10-30
恩威医药（301331）披露2023年限制性股票激励计划第二期归属条件成就，10月30日股价下跌4.28%
恩威医药(301331)9月30日股东户数0.63万户，较上期减少13.72%
证券之星 · 2025-10-30
恩威医药(301331)9月30日股东户数0.63万户，较上期减少13.72%
恩威医药（301331）6979.02万股限售股将于9月25日解禁，占总股本67.83%
证券之星 · 2025-09-25
恩威医药（301331）6979.02万股限售股将于9月25日解禁，占总股本67.83%
恩威医药（301331）披露关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告，9月22日股价上涨0.89%
证券之星 · 2025-09-22
恩威医药（301331）披露关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告，9月22日股价上涨0.89%
股市必读：恩威医药（301331）9月3日披露最新机构调研信息
证券之星 · 2025-09-04
股市必读：恩威医药（301331）9月3日披露最新机构调研信息
恩威医药（301331）股东成都恩威投资(集团)有限公司质押750万股，占总股本7.3%
证券之星 · 2025-08-27
恩威医药（301331）股东成都恩威投资(集团)有限公司质押750万股，占总股本7.3%
恩威医药（301331）2025年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 2025-08-27
恩威医药（301331）2025年中报简析：营收净利润同比双双增长，应收账款上升
恩威医药(301331.SZ)：上半年净利润3834.42万元 同比增长113.80%
格隆汇 · 2025-08-25
恩威医药(301331.SZ)：上半年净利润3834.42万元 同比增长113.80%
恩威医药股价上涨3.46% 子公司完成药品生产许可证换发
金融界 · 2025-08-19
恩威医药股价上涨3.46% 子公司完成药品生产许可证换发
加载更多
公司概况
公司名称：
恩威医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是洁尔阴洗液、洁尔阴软膏、洁尔阴泡腾片、健儿药丸、山麦健脾口服液、化瘀舒经胶囊、益肺健脾颗粒、感冒舒颗粒。
发行价格：
29.80
{"stockData":{"symbol":"301331","market":"SZ","secType":"STK","nameCN":"恩威医药","latestPrice":29.61,"timestamp":1768977189000,"preClose":29.06,"halted":0,"volume":3049751,"delay":0,"changeRate":0.0189,"floatShares":103000000,"shares":103000000,"eps":0.506,"marketStatus":"交易中","change":0.55,"latestTime":"01-21 14:33:09","open":29.98,"high":30.5,"low":29.28,"amount":90994200,"amplitude":0.042,"askPrice":29.63,"askSize":1,"bidPrice":29.62,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.506,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768978800000},"marketStatusCode":2,"adr":0,"adjPreClose":29.06,"symbolType":"stock","openAndCloseTimeList":[[1768959000000,1768966200000],[1768971600000,1768978800000]],"highLimit":31.97,"lowLimit":26.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":102891887,"isCdr":false,"pbRate":2.76,"roa":"--","peRate":58.517787,"roe":"3.42%","epsLYR":0.3728,"committee":0.504,"marketValue":3047000000,"turnoverRate":0.0297,"status":0,"floatMarketCap":3041000000},"requestUrl":"/m/hq/s/301331","defaultTab":"news","newsList":[{"id":"2604919937","title":"恩威医药最新公告：2025年净利润同比预增50.68%至77.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919937","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604919937?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:49","pubTimestamp":1768902585,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)披露2025年度业绩预告，预计2025年归母净利润为5650万元至6650万元，同比增长50.68%至77.35%。2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000028682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2595782447","title":"恩威医药（301331）披露2025年中期分红派息实施公告，12月31日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595782447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595782447?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:11","pubTimestamp":1767175883,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，恩威医药报收于26.44元，较前一交易日上涨0.23%，最新总市值为27.2亿元。该股当日开盘26.42元，最高26.58元，最低26.25元，成交额达1840.99万元，换手率为0.68%。近日，恩威医药股份有限公司发布2025年中期分红派息实施公告。股权登记日为2026年1月7日，除权除息日为2026年1月8日。分红后将调整相关股东减持价格承诺及限制性股票授予价格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2595786735","title":"恩威医药（301331）披露2025年中期分红方案，12月29日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595786735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595786735?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:46","pubTimestamp":1767001574,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，恩威医药报收于26.63元，较前一交易日下跌0.34%，最新总市值为27.4亿元。该股当日开盘26.85元，最高26.85元，最低26.38元，成交额达2190.56万元，换手率为0.8%。近日，恩威医药发布关于公司2025年中期分红方案的公告。根据公告内容，公司于2025年12月26日召开第三届董事会第九次会议，审议通过2025年中期分红方案。该方案在2024年年度股东会授权范围内，无需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900024466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2593230954","title":"恩威医药：海南定安恩威实业有限公司与公司已无关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2593230954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593230954?lang=zh_cn&edition=full","pubTime":"2025-12-24 11:37","pubTimestamp":1766547467,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药(301331)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下董秘，海南定安恩威实业有限公司跟贵公司有没有关联？恩威医药回复：您好！感谢您对公司的关注！海南定安恩威实业有限公司是公司控股股东恩威集团早期（上市前）在海南注册成立的经营实体，后随着恩威集团发展方向调整，逐步停止了该公司的运营，并于2018年转让了该公司全部股权。自此，海南定安恩威实业有限公司与公司已不存在任何关联关系。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400014719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2589435996","title":"恩威医药（301331）披露关于控股股东部分股份解除质押的公告，12月8日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589435996","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589435996?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:23","pubTimestamp":1765203819,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，恩威医药报收于28.77元，较前一交易日上涨0.03%，最新总市值为29.6亿元。公司近日发布公告称，接到控股股东成都恩威投资（集团）有限公司通知，其持有的4,000,000股公司股份已于2025年12月5日解除质押，占其所持股份比例13.45%，占公司总股本比例3.89%。截至公告日，恩威集团持有公司29,733,200股，占总股本28.90%；其一致行动人合计持股71,101,168股，累计质押股份50,420,836股，占其所持股份70.91%，占公司总股本49.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2584004133","title":"恩威医药：呼吸系统用药是公司重要的产品线之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2584004133","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584004133?lang=zh_cn&edition=full","pubTime":"2025-11-20 18:39","pubTimestamp":1763635140,"startTime":"0","endTime":"0","summary":"证券日报网讯恩威医药11月20日在互动平台回答投资者提问时表示，呼吸系统用药是公司重要的产品线之一，其中多款产品可用于缓解感冒症状：复方银翘氨敏胶囊、复方氨酚烷胺片、小儿氨酚黄那敏颗粒，另外，公司今年新推出的信心药业复产品种抗病毒口服液，包含板蓝根、地黄、连翘等9种中草药成分，具有清热祛湿，凉血解毒功效，可用于风热感冒，流感。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infxzzst2619761.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infxzzst2619761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2584180024","title":"恩威医药（301331）股东成都恩威投资(集团)有限公司质押500万股，占总股本4.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584180024","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584180024?lang=zh_cn&edition=full","pubTime":"2025-11-20 18:38","pubTimestamp":1763635112,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药11月20日公开信息显示，股东成都恩威投资(集团)有限公司向上海银行股份有限公司成都分行合计质押500.0万股，占总股本4.86%。恩威医药主营业务：中成药及化学药的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000029069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2584970652","title":"恩威医药：多款产品可用于流感治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2584970652","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584970652?lang=zh_cn&edition=full","pubTime":"2025-11-20 08:45","pubTimestamp":1763599517,"startTime":"0","endTime":"0","summary":"呼吸系统用药是公司重要的产品线之一，其中多款产品可用于缓解感冒症状：复方银翘氨敏胶囊、复方氨酚烷胺片、小儿氨酚黄那敏颗粒，另外，公司今年新推出的信心药业复产品种抗病毒口服液，包含板蓝根、地黄、连翘等9种中草药成分，具有清热祛湿，凉血解毒功效，可用于风热感冒，流感。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000004555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2583897507","title":"恩威医药（301331）披露2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市公告，11月14日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583897507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583897507?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:58","pubTimestamp":1763132301,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，恩威医药报收于32.37元，较前一交易日下跌0.77%，最新总市值为33.31亿元。近日，恩威医药发布关于2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市的公告。公告显示，公司已于2025年11月14日完成该批次的归属登记，本次实际归属股票数量为76.02万股，占公司总股本的0.7388%。归属对象为105名激励对象，另有1名高级管理人员因避免短线交易暂缓归属。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2583729335","title":"恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2583729335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583729335?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:30","pubTimestamp":1763116251,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)公告称，公司作为有限合伙人以自有资金认缴出资2000万元，参与设立嘉兴磐霖嘉颐创业投资合伙企业（有限合伙）。该基金规模为20100万元，投资方向包括医疗（创新药、创新医疗器械）及科技（企业级服务、硬科技）等。合伙企业尚需完成中国证券投资基金业协会备案和工商变更登记手续，实施过程存在不确定性。公司本次投资可能面临较长的投资回报期，以及投资项目不能实现预期收益或投资失败的风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400032547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2579645104","title":"恩威医药（301331）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2579645104","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579645104?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:57","pubTimestamp":1761865074,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩威医药发布2025年三季报。根据财报显示，恩威医药营收净利润同比双双增长。截至本报告期末，公司营业总收入6.37亿元，同比上升13.65%，归母净利润3658.47万元，同比上升66.13%。去年的净利率为4.62%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2579112838","title":"恩威医药（301331）披露2023年限制性股票激励计划第二期归属条件成就，10月30日股价下跌4.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579112838","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579112838?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:41","pubTimestamp":1761820863,"startTime":"0","endTime":"0","summary":"近日，恩威医药发布关于2023年限制性股票激励计划第二期归属条件成就的公告。公司层面业绩考核方面，2024年营业收入较2022年增长17.43%，达到门槛值，公司层面可归属比例为80%；个人层面考核结果均为优秀/良好，归属比例为100%。董事会认为第二期归属条件已成就，同意办理相关归属手续。部分未达条件的限制性股票合计21.8821万股将被作废。本次归属不会导致公司总股本变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31751796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2579113266","title":"恩威医药(301331)9月30日股东户数0.63万户，较上期减少13.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579113266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579113266?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:49","pubTimestamp":1761817792,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩威医药披露，截至2025年9月30日公司股东户数为6340.0户，较6月30日减少1008.0户，减幅为13.72%。在中药行业个股中，恩威医药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.35万户。从股价来看，2025年6月30日至2025年9月30日，恩威医药区间涨幅为0.06%，在此期间股东户数减少1008.0户，减幅为13.72%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2570034479","title":"恩威医药（301331）6979.02万股限售股将于9月25日解禁，占总股本67.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570034479","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570034479?lang=zh_cn&edition=full","pubTime":"2025-09-25 08:01","pubTimestamp":1758758517,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，恩威医药于9月25日将有6979.02万股限售股份解禁，为公司首发原股东限售股份，占公司总股本67.83%。本次解禁后，公司还有19.61万股限售股份，占总股本0.19%。恩威医药主营业务：中成药及化学药的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500003774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2569733127","title":"恩威医药（301331）披露关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告，9月22日股价上涨0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569733127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569733127?lang=zh_cn&edition=full","pubTime":"2025-09-22 22:48","pubTimestamp":1758552504,"startTime":"0","endTime":"0","summary":"公司近日发布《关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告》。公告显示，本次解除限售股东共5户，解除限售股份数量为69,790,184股，占公司总股本的67.83%，限售期为36个月。解除限售股份上市流通日期为2025年9月25日。本次解除限售后，公司有限售条件股份由69,986,254股减少至196,070股，无限售条件股份由32,905,633股增加至102,695,817股，总股本不变。保荐机构对本次解除限售无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200035037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2564950319","title":"股市必读：恩威医药（301331）9月3日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2564950319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564950319?lang=zh_cn&edition=full","pubTime":"2025-09-04 04:04","pubTimestamp":1756929857,"startTime":"0","endTime":"0","summary":"截至2025年9月3日收盘，恩威医药报收于33.97元，下跌2.86%，换手率4.2%，成交量1.38万手，成交额4759.37万元。来自机构调研要点：2025年上半年归母净利润同比增长113.80%，主要得益于河南信心药业重点产品复产上市、线上非药类产品销售增长及摊销费用下降。公司收购河南信心药业是战略布局的关键一步，旨在拓展产品矩阵及市场覆盖，从而提升业绩水平。截至目前，公司尚未获悉大股东及其一致行动人关于减持其所持有股份意向的通知或信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400002890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2562717755","title":"恩威医药（301331）股东成都恩威投资(集团)有限公司质押750万股，占总股本7.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562717755","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562717755?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:42","pubTimestamp":1756291321,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药8月27日公开信息显示，股东成都恩威投资(集团)有限公司向徐英壮、浙江香溢元泰典当有限责任公司、上海金汇利典当有限公司合计质押750.0万股，占总股本7.3%。恩威医药主营业务：中成药及化学药的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700039919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2562763710","title":"恩威医药（301331）2025年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2562763710","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562763710?lang=zh_cn&edition=full","pubTime":"2025-08-27 06:35","pubTimestamp":1756247751,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩威医药发布2025年中报。截至本报告期末，公司营业总收入4.49亿元，同比上升15.73%，归母净利润3834.42万元，同比上升113.8%。按单季度数据看，第二季度营业总收入2.53亿元，同比上升23.48%，第二季度归母净利润2203.91万元，同比上升131.73%。本报告期恩威医药应收账款上升，应收账款同比增幅达48.13%。本次财报公布的各项数据指标表现尚佳。筹资活动产生的现金流量净额变动幅度为-126.5%,原因:上年同期新增银行贷款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700009815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2562249028","title":"恩威医药(301331.SZ)：上半年净利润3834.42万元 同比增长113.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562249028","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562249028?lang=zh_cn&edition=full","pubTime":"2025-08-25 20:09","pubTimestamp":1756123788,"startTime":"0","endTime":"0","summary":"格隆汇8月25日丨恩威医药(301331.SZ)公布2025年半年度报告，上半年公司实现营业收入4.49亿元，同比增长15.73%；归属于上市公司股东的净利润3834.42万元，同比增长113.80%；归属于上市公司股东的扣除非经常性损益的净利润3527.57万元，同比增长132.47%；基本每股收益0.3845元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/25200952675168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301331"],"gpt_icon":0},{"id":"2560419573","title":"恩威医药股价上涨3.46% 子公司完成药品生产许可证换发","url":"https://stock-news.laohu8.com/highlight/detail?id=2560419573","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560419573?lang=zh_cn&edition=full","pubTime":"2025-08-19 19:41","pubTimestamp":1755603707,"startTime":"0","endTime":"0","summary":"截至2025年8月19日收盘，恩威医药股价报36.45元，较前一交易日上涨3.46%。当日成交量为20416手，成交额达0.74亿元。消息面上，恩威医药全资子公司河南信心药业近日完成药品生产许可证换发，涉及片剂、颗粒剂、散剂等多种剂型。该许可证有效期至2025年12月31日。此外，健儿药丸和清肝利胆口服液两个品种已完成委托生产许可换发，待生产地址变更及关联备案后即可投产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/19194152543257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","301331"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768977194217,"stockEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":0.0947},{"period":"3month","weight":-0.0553},{"period":"6month","weight":-0.1953},{"period":"1year","weight":0.2494},{"period":"ytd","weight":0.1129}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0574},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1409},{"period":"1year","weight":0.2679},{"period":"ytd","weight":0.0365}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"恩威医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6340人(较上一季度减少13.72%)","perCapita":"16198股","listingDate":"2022-09-21","address":"西藏自治区昌都市卡若区经开区A坝区创业大道恩威大厦","registeredCapital":"10289万元","survey":" 恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是洁尔阴洗液、洁尔阴软膏、洁尔阴泡腾片、健儿药丸、山麦健脾口服液、化瘀舒经胶囊、益肺健脾颗粒、感冒舒颗粒。","listedPrice":29.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩威医药,301331,恩威医药股票,恩威医药股票老虎,恩威医药股票老虎国际,恩威医药行情,恩威医药股票行情,恩威医药股价,恩威医药股市,恩威医药股票价格,恩威医药股票交易,恩威医药股票购买,恩威医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}